Avelumab and Merkel Cell Carcinoma Risk: What Studies Show

From General Health Information to Occupational Exposure Concerns

Historically, public health communication has centered on general wellness and broad disease prevention, often drawing from established biomedical knowledge to guide lifestyle choices. This legacy framework effectively disseminated information on topics such as vaccination, nutrition, and chronic disease management, relying on consensus-driven science to inform populations. Within this context, discussions of pharmaceutical interventions typically emphasized therapeutic benefits and safety profiles derived from clinical trials, without delving into specific causal pathways or occupational exposures. As the scope of health science expands, attention increasingly turns to the intersection of therapeutic agents and environmental risk factors encountered in professional settings. The transition from general health information to occupational exposure concerns requires a focused shift: moving from population-level advice to the scrutiny of specific substances and their potential links to adverse outcomes in workers. In particular, the biologic agent Avelumab, an immune checkpoint inhibitor used in oncology, has prompted investigation into its association with Merkel cell carcinoma risk. This pivot reframes the discussion from broad health education to a targeted examination of exposure scenarios, where the question is not merely about general safety but about the implications for individuals who may encounter such agents in their work environment.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Etiology of Merkel Cell Carcinoma and Role of Immune Checkpoint Inhibitors

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus; approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit in advanced MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% do not respond or develop immune-related adverse events due to diverse mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, clinical and molecular data of patients with metastatic MCC refractory to avelumab who were later treated with combined ipilimumab and nivolumab were collected and evaluated; three out of five patients responded to combined therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC noted that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Risk Context: Avelumab as Treatment, Not Cause

Regarding causation-related considerations, avelumab is an approved therapeutic agent for metastatic MCC, and its use is associated with both therapeutic responses and potential adverse effects. The timeline between exposure to avelumab and documented harm in the context of MCC primarily involves disease progression or immune-related adverse events rather than causation of the disease itself. The evidence indicates that avelumab is used to treat MCC, not to cause it. The risk narrative therefore centers on the adequacy of warnings regarding avelumab's efficacy and safety profile in treating MCC, including the risk of non-response or progression. The JAVELIN Merkel 200 trial provided the basis for approval, with objective responses in about one-third of patients, meaning that a majority of patients did not achieve a confirmed response (https://pubmed.ncbi.nlm.nih.gov/29799096/). Warnings should address that approximately 50% of patients may not respond or may develop immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/34445385/). For avelumab-refractory patients, alternative treatments such as combined ipilimumab and nivolumab have shown some efficacy, but data are limited to small retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In summary, avelumab is a PD-L1 inhibitor approved for metastatic MCC based on clinical trial evidence showing objective responses in a subset of patients. The risk of non-response or progression is substantial, with about half of patients not benefiting from therapy. Causation of MCC by avelumab is not supported by the evidence; rather, avelumab is a treatment for the disease. Adequate warnings should inform patients and clinicians about the likelihood of response, the potential for immune-related adverse events, and the limited options for those who are refractory to avelumab.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor approved for metastatic MCC based on clinical trials showing objective responses in a subset of patients. The evidence does not support avelumab causing MCC.

What are the risks of avelumab treatment for Merkel cell carcinoma?

Approximately 50% of patients may not respond or may develop immune-related adverse events. The JAVELIN Merkel 200 trial showed objective responses in about one-third of patients, meaning a majority did not achieve a confirmed response. For those refractory to avelumab, alternative treatments like combined ipilimumab and nivolumab have limited data.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.